Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 14/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 14/20 | 0.50 |
| ▸ | CTSK | P43235 | 4/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4770801 | 0.86 | TAS1R3 (0.49) | TAS1R3TAS1R1CTSKCTSLCTSS | |
| SCHEMBL4770805 | 0.86 | TAS1R3 (0.49) | TAS1R3TAS1R1CTSKCTSLCTSS | |
| SCHEMBL4765540 | 0.83 | NPC1 (0.37) | TAS1R3TAS1R1CTSKCTSLCTSS | |
| SCHEMBL4763005 | 0.81 | TAS1R3 (0.48) | TAS1R3TAS1R1CTSKCTSSCTSB | |
| SCHEMBL4770834 | 0.81 | TAS1R3 (0.51) | TAS1R3TAS1R1CTSKCTSLCTSS | |
| SCHEMBL4770836 | 0.81 | TAS1R3 (0.51) | TAS1R3TAS1R1CTSKCTSLCTSS | |
| SCHEMBL6605727 | 0.80 | NPC1 (0.37) | ALDH1A1NPC1 | |
| SCHEMBL7425840 | 0.80 | TAS1R3 (0.48) | TAS1R3TAS1R1CTSKCTSLCTSS | |
| SCHEMBL4762072 | 0.80 | TAS1R3 (0.49) | TAS1R3TAS1R1CTSKCTSLCTSS | |
| SCHEMBL7426728 | 0.79 | TAS1R3 (0.47) | TAS1R3TAS1R1CTSKCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320370-A4 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1320370-A1 | METHOD OF TREATMENT | SmithKline Beecham Corporation (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002017924-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-03-07 | — | — | WO | disclosed |